Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

September 28, 2023

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies

September 26, 2023

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

September 13, 2023

Financial Events

H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023

Imunon’s Second Quarter 2023 Financial Results

August 10, 2023 at 11:00 AM EDT